Company Overview and News
(Oct 5): Kenanga Investment Bank Bhd analyst Marie Vaz upgraded the recommendation on Capitaland Malaysia Mall Trust (CMMT) to outperform from market perform.
Real estate investment trust sector Maintain neutral: There are no surprises for 2QCY18 earnings for real estate investment trusts (REIT). Core net income (CNI) of the six out of the seven REITs under our coverage were in line with our full-year forecasts.
MIDF Research noted that Axis REIT has handed over Axis Mega Distribution Centre to Nestle and is now working on the Axis Aerotech [email protected] with a development cost of RM74.2mil, expected to be completed by the fourth quarter of this year.
CapitaLand Malaysia Mall Trust (July 26, RM1.23) Maintain neutral with an unchanged target price (TP) of RM1.11: First half of financial year 2018 (1HFY18) earnings largely within estimates. CapitaLand Malaysia Mall Trust’s (CMMT) 1HFY18 core net income (CNI) of RM70.7 million was largely in line with our full-year expectations, making up 44.4% of our full-year forecast and 44.9% of consensus’. A distribution per unit (DPU) of two sen was announced, which is also within our estimates.
KUALA LUMPUR (July 27): CIMB IB Research has maintained its “Hold” rating on CapitaLand Malaysia Mall Trust (CMMT) at RM1.24 with a higher target price of RM1.25 (from RM1.09) and said CMMT’s 1H18 core net profit was broadly in line at 44-45% of house and consensus numbers.
KUALA LUMPUR (July 25): Based on corporate announcements and news flow today, companies that may be in focus on Thursday (July 26) may include the following: Westports Holdings Bhd, Star Media Group Bhd, JAKS Resources Bhd, Cuscapi Bhd, Uzma Bhd, Marine & General Bhd, Vizione Holdings Bhd, D’nonce Technology Bhd, Capitaland Malaysia Mall Trust, Gadang Holdings Bhd, M-Mode Bhd and Mega First Corporation Bhd.
9261 6084 5180 4723 5246 BSMAF MGFCF 1818
KUALA LUMPUR (July 25): CapitaLand Malaysia Mall REIT Management Sdn Bhd (CMRM), the manager of CapitaLand Malaysia Mall Trust (CMMT), announced today that CMMT achieved net property income (NPI) of RM53.4 million for the second quarter of its financial year ending Dec 31, 2018 (2QFY18), which was 10.8% lower than its 2QFY17 NPI of RM59.8 million.
5180 BSMAF 1818
AL-SALAM Real Estate Investment Trust, one of the two REITs in the Johor Corp group, is aiming to acquire almost RM1 billion worth of commercial and industrial assets over the next three years.
5269 5180 BSMAF 1818
KUALA LUMPUR: JF Apex Research expects Unisem (M) Bhd , Globetronics Technology Bhd , CapitaLand Malaysia Mall Trust (CMMT), Minetech Resources Bhd and Syarikat Takaful Malaysia Bhd to attract trading interest today.
6139 7219 5180 7022 GBTKF
CapitaLand Malaysia Mall Reit Management Sdn Bhd CEO Low Peck Chen, CMMT’s manager, said CMMT achieved a positive rental reversion of 2.2% and a stable portfolio occupancy remained stable of 93.7% as at March 31, 2018, amidst a challenging operating environment.
5180 BSMAF 1818
Downtrend: At yesterday’s close, the fall of MREITs widened considerably year to date with CapitaLand Malaysia Mall Trust (CMMT) seeing a 40.2 decline, diversified Sunway REIT (13.09), PavREIT (9.85), AxisREIT (16.77) and IGB REIT (12.98).
CapitaLand Malaysia Mall Trust (CMMT)’s share price has declined 30% year-to-date and is below the initial public offering (IPO) price of RM1.08 (in 2010).
1562 SMEBF 5180 4197
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...